跳至主要内容

What is Toxicokinetics?

 Toxicokinetics is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics.

Four processes in toxicokinetics

The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances.

Frequently the terms toxicokinetics, pharmacokinetics, or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?).

The disposition of a toxicant along with its’ biological reactivity are the factors that determine the severity of toxicity that results when a xenobiotic enters the body. Specific aspects of disposition of greatest importance are:

  • Duration and concentration of substance at the portal of entryrate and amount that can be absorbed
  • Distribution in the body and concentration at specific body sites
  • Efficiency of biotransformation and nature of the metabolites
  • The ability of the substance or it’s metabolites to pass through cell membranes and come into contact with specific cell components (e.g., DNA).
  • The amount and duration of storage of the substance (or it’s metabolites) in body tissues
  • The rate and sites of excretion

Examples of how toxicokinetics of a substance can influence its toxicity:

Absorption: A highly-toxic substance, which is poorly absorbed, may be no more of a hazard than a substance of low toxicity that is highly absorbed.

Biotransformation: Two substances with equal toxicity and absorption may differ in hazard depending on the nature of their biotransformation. A substance biotransformed into a more toxic metabolite (bioactivated) is a greater hazard than a substance that is biotransformed into a less toxic metabolite (detoxified).

Absorption, distribution, biotransformation, and elimination are inter-related processes as illustrated in the following figure.


The toxicokinetics literature is extensive and a listing of all the excellent toxicology and toxicokinetics textbooks is beyond the scope of this tutorial. While other references were occasionally consulted, the textbooks listed below have served as the primary resources for this tutorial.

Related Articles:

Toxicokinetics Test Service Company

Pharmacokinetic test / toxicokinetic test

Contact Us 

Email : marketing@medicilon.com

Tel : +86 021 58591500



标签：

评论

发表评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou
发表评论
阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d
发表评论
阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati
发表评论
阅读全文